Amgen’s Aranesp Reimbursement Continues To Get Scrutiny From Capitol Hill
Executive Summary
The debate around Medicare reimbursement for Amgen's anemia treatments Aranesp and Epogen is being reopened by House Ways & Means Committee Chairman Bill Thomas (R-Calif.) as CMS drafts its annual payment update rule that addresses the issue
You may also be interested in...
Medicare’s Overdue Study On Changing EPO Payment Now Promised For 2007
A rapid change in Medicare policy on reimbursement for Amgen's Epogen (epoetin alfa) used in dialysis facilities is unlikely, despite impassioned criticism of the current policy from outgoing House Ways and Means Committee Chairman Bill Thomas (R-Calif.)
Medicare’s Overdue Study On Changing EPO Payment Now Promised For 2007
A rapid change in Medicare policy on reimbursement for Amgen's Epogen (epoetin alfa) used in dialysis facilities is unlikely, despite impassioned criticism of the current policy from outgoing House Ways and Means Committee Chairman Bill Thomas (R-Calif.)
Excessive EPO Use Will Be Examined In House Ways & Means Hearing
Representatives from the Government Accountability Office, CMS and FDA are expected to testify at a Dec. 6 House Ways & Means Committee hearing on controlling utilization of Amgen's EPO products Epogen and Aranesp in dialysis facilities